News
The FDA has approved Axert (almotriptan malate tablets, from Ortho-McNeil Janssen), a selective 5-HT1B/1D receptor agonist, for the acute treatment of migraine headache in adolescents 12–17 ...
Medicine Chest Axert WHAT: Axert (almotriptan malate), a new, prescription-only member of the triptan family of drugs, from Pharmacia. TREATS: Adults' migraine headaches with or without aura.
Teva announced the launch of Almotriptan Malate Tablets, the generic version of Janssen's Axert.
Axert has been approved by the FDA for the acute treatment of migraine with or without aura in adults.
On June 1, the FDA approved revisions to the safety labeling for almotriptan malate tablets (Axert, made by Janssen Ortho), to include reports of serious adverse cardiac events, including acute ...
The FDA has approved an expanded indication for almotriptan malate (Axert) for the acute treatment of migraine headache in adolescents aged 12 to 17 years.
Teva has launched the generic version of almotriptan malate (Axert), 6.25 mg and 12.5 mg, in the United States. According to the press release, Teva is the first applicant to submit an abbreviated new ...
According to IMS, Axert generated $31M in sales for the 12-month period ending in March. Teva markets over 375 generic medicines.
Teva continues to deliver on its generics business strategy and remains focused on increasing its first to file regulatory submissions in the United States. With over 375 generic medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results